If you've been told you have a brain tumor, either as a result of a routine checkup or in the course of having some symptoms evaluated, all is not lost. Many low grade tumors can be resected and controlled. More aggressive tumors can be treated more aggressively. These high grade tumors undergo an attack using our arsenal of traditional and experimental therapies, giving you the best chance for survival and the best quality of life while undergoing treatment.
|Dr. Timothy Cloughesy gives a detailed overview of how Translational Brain Cancer Research at UCLA rapidly brings developments from the research setting to the patient bedside. View the presentation |
Despite the continued advancement of experimental therapies and diagnostic technologies, malignant brain tumors are still among the most morbid and devastating tumors of children and adults. The annual incidence of intracranial CNS tumors ranges from 10 to 17 per 100,000 persons. Tumors of glial origin account for about 90% of adult primary, malignant brain tumors. Although by incidence these tumors seem relatively rare, they are the leading cause of cancer death in the pediatric age group, the second leading cause of cancer mortality in people under 35, the fourth leading cause in individuals under the age of 54, and have significant public health implications. There is some evidence that the incidence in the elderly has increased over the last few decades (Greig et al 1990, Boyle et al 1990). In the United States an estimated 13,300 people will die annually from primary nervous system tumors, and 17,200 will be diagnosed (Preston-Martin 1996).
How our patients respond:
At UCLA, our mission is to provide patients with the best possible care using our multi-disciplinary team of experts from Medical Oncology, Neurosurgery, Neurology, Radiation Oncology, Biology, Genetics, Psychiatry, Psychology, Neuroradiology, Neuropathology and Computer Science. You can feel confident every member of our team is a world-class expert in their field, and apply their highly specialized skill set to eradicate your tumor.
When choosing a treatment center it is important to realize that 99% of all clinics will not be able to tell you exactly how well their patients are performing. Our program is radically different. We use advanced database and data management software to track each patient that comes through our doors. This predictive modeling and data management software helps link every specialists in our team, ensuring everyone is on the same page when formulating your treatment plan of attack. Our software also looks at 10 years of treatment plans, and determines which treatment plans have worked for a particular group and which treatment plans have not.
UCLA Neuro-Oncology is also different in that we are often the first institution to offer Phase I and Phase II clinical trials. We work independently with leading bio-tech firms to secure these cutting edge therapeutic agents. In addition, our program is also a member of the North American Brain Tumor Consortium (NABTC). The NABTC works on our behalf to further secure clinical trial openings for our patients.
Combine these advanced technologies, access to emerging clinical trials with a dedicated clinical and support care team, and the result equates to our patients surviving at least 50% longer when compared to non-research based hospitals(*), and an extraordinary quality of life for patients under going therapy.